Johnson & Johnson fined $8 billion in a case over male breast growth
Johnson & Johnson has been told to pay $8bn to a man claims over an anti-psychotic drug that could grow breast.
The American company Johnson & Johnson, which has been in controversy over its products, has once again fallen into trouble.
The Philadelphia Court of Common Pleas jury made the award to Nicholas Murray, 26, awarding punitive damages in one of the thousands of Risperdal cases pending in the state.
Murray says he developed breasts after he began taking Risperdal in 2003, according to Reuters.
Tom Kline and Jason Itkin, Murray’s lawyers, in a statement said that argued J&J’s subsidiary Janssen Pharmaceutica put “profits over patients” in marketing the drug Risperdal.
At the same time, Johnson & Johnson said that the evidence presented on its behalf in the case was “grossly disproportionate”. The penalty exacted on the company is irreconcilable, and they will again file a petition in the High Court.
The US drug firm is facing several complaints about allegedly failing to warn of Risperdal’s side effects adequately.
In August, court-ordered J&J to pay $572m for its part in fuelling Oklahoma’s opioid addiction crisis, a judge in the US state has ruled.